ANGN
Income statement / Annual
Last year (2024), Angion Biomedica Corp.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Angion Biomedica Corp.'s net income was -$51.90 M.
See Angion Biomedica Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2024 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$0.00 |
$2.30 M |
$28.31 M |
$2.88 M |
$1.49 M |
$4.03 M |
$6.58 M |
$7.30 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$433.00 K
|
$1.19 M
|
$640.00 K
|
$378.00 K
|
$3.17 M
|
$3.67 M
|
| Gross Profit |
$0.00
|
$2.30 M
|
$27.88 M
|
$1.69 M
|
$847.00 K
|
$3.65 M
|
$3.41 M
|
$3.62 M
|
| Gross Profit Ratio |
0
|
1
|
0.98
|
0.59
|
0.57
|
0.91
|
0.52
|
0.5
|
| Research and Development Expenses |
$33.66 M
|
$18.10 M
|
$48.70 M
|
$38.98 M
|
$29.84 M
|
$12.60 M
|
$196.01 K
|
$0.00
|
| General & Administrative Expenses |
$11.33 M
|
$14.64 M
|
$18.49 M
|
$17.99 M
|
$9.60 M
|
$5.39 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.33 M
|
$14.64 M
|
$18.49 M
|
$17.99 M
|
$9.60 M
|
$5.39 M
|
$0.00
|
$0.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.61 M
|
$4.04 M
|
| Operating Expenses |
$44.99 M
|
$32.74 M
|
$67.19 M
|
$56.96 M
|
$39.44 M
|
$17.99 M
|
$3.81 M
|
$4.04 M
|
| Cost And Expenses |
$0.00
|
$32.74 M
|
$67.62 M
|
$58.15 M
|
$40.08 M
|
$18.37 M
|
$6.98 M
|
$7.72 M
|
| Interest Income |
$777.00 K
|
$0.00
|
$0.00
|
$0.00
|
$265.00 K
|
$252.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
-$455.00 K
|
$805.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$300.43 K
|
$307.45 K
|
| Depreciation & Amortization |
$0.00
|
$10.32 M
|
$801.00 K
|
$628.00 K
|
$2.47 M
|
$2.00 K
|
$460.34 K
|
$463.22 K
|
| EBITDA |
-$44.99 M |
-$20.12 M |
-$55.62 M |
-$88.33 M |
-$36.12 M |
-$20.02 M |
$1.85 M |
$1.28 M |
| EBITDA Ratio |
0
|
-8.74
|
-1.96
|
-30.67
|
-24.29
|
-4.97
|
0.28
|
0.18
|
| Operating Income Ratio |
0
|
-13.23
|
-1.39
|
-19.19
|
-25.95
|
-3.56
|
-0.06
|
-0.06
|
| Total Other Income/Expenses Net |
-$6.91 M
|
-$8.37 M
|
-$15.27 M
|
-$24.83 M
|
-$2.07 M
|
-$5.68 M
|
$2.13 M
|
$1.61 M
|
| Income Before Tax |
-$51.90 M
|
-$38.81 M
|
-$54.57 M
|
-$80.11 M
|
-$40.66 M
|
-$20.03 M
|
$1.73 M
|
$1.19 M
|
| Income Before Tax Ratio |
0
|
-16.87
|
-1.93
|
-27.81
|
-27.34
|
-4.97
|
0.26
|
0.16
|
| Income Tax Expense |
$0.00
|
$16.89 M
|
-$801.00 K
|
-$628.00 K
|
$1.71 M
|
$0.00
|
$452.78 K
|
$201.86 K
|
| Net Income |
-$51.90 M
|
-$55.70 M
|
-$53.77 M
|
-$79.48 M
|
-$42.37 M
|
-$20.03 M
|
$632.24 K
|
$307.30 K
|
| Net Income Ratio |
0
|
-24.21
|
-1.9
|
-27.6
|
-28.49
|
-4.97
|
0.1
|
0.04
|
| EPS |
-4.25 |
-1.85 |
-1.9 |
-2.76 |
-2.51 |
-1.3 |
0.0374 |
0.0182 |
| EPS Diluted |
-4.25 |
-1.85 |
-1.9 |
-2.76 |
-2.51 |
-1.3 |
0.0374 |
0.0182 |
| Weighted Average Shares Out |
$12.20 M
|
$30.04 M
|
$28.24 M
|
$28.78 M
|
$16.90 M
|
$15.36 M
|
$16.90 M
|
$16.90 M
|
| Weighted Average Shares Out Diluted |
$12.20 M
|
$30.04 M
|
$28.24 M
|
$28.78 M
|
$16.90 M
|
$15.36 M
|
$16.90 M
|
$16.90 M
|
| Link |
|
|
|
|
|
|
|
|
